ScinoPharm (TWSE:1789) announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of delafloxacin active pharmaceutical ingredient (“API”) for Melinta’s Baxdela™,

International Inc. (NYSE: BAX) and ScinoPharm Taiwan, Ltd. (TWSE: 1789) today announced a strategic partnership to develop, manufacture and commercialize five injectable drugs used in a range of cancer treatments,

ScinoPharm Taiwan, Ltd (TWSE: 1789), an active pharmaceutical ingredient (API) and formulation specialty company, announced unaudited financial results for its fiscal year 2016.